Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Rheumatoid arthritis in 2013

Translational medicine in RA—time for change

With every passing year, research on the pathogenesis of rheumatoid arthritis benefits from discoveries in other scientific fields. Three of the best examples that illustrate the benefit of such interdisciplinary bridges and the effects they have on our understanding of rheumatoid arthritis are presented here.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Translational medicine and clinical development.

References

  1. Miossec, P. & Kolls, J. K. Targeting IL-17 and TH17 cells in chronic inflammation. Nat. Rev. Drug Discov. 11, 763–776 (2012).

    Article  CAS  Google Scholar 

  2. Nie, H. et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat. Med. 19, 322–328 (2013).

    Article  CAS  Google Scholar 

  3. Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006).

    Article  CAS  Google Scholar 

  4. McGovern, J. L. et al. TH17 cells are restrained by TREG cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum. 64, 3129–3138 (2012).

    Article  CAS  Google Scholar 

  5. Alzabin, S. et al. Incomplete response of inflammatory arthritis to TNFα blockade is associated with the TH17 pathway. Ann. Rheum. Dis. 71, 1741–1748 (2012).

    Article  CAS  Google Scholar 

  6. Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl Acad. Sci. USA 110, 3507–3512 (2013).

    Article  CAS  Google Scholar 

  7. Lee, J. C. et al. Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 155, 57–69 (2013).

    Article  CAS  Google Scholar 

  8. Turrel-Davin, F. et al. FoxO3a involved in neutrophil and T cell survival is overexpressed in rheumatoid blood and synovial tissue. Ann. Rheum. Dis. 69, 755–760 (2010).

    Article  CAS  Google Scholar 

  9. Gregersen, P. K. & Manjarrez-Orduño, N. FOXO in the hole: leveraging GWAS for outcome and function. Cell 155, 11–12 (2013).

    Article  CAS  Google Scholar 

  10. Miossec, P. et al. Biomarkers and personalised medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann. Rheum. Dis. 70, 1713–1718 (2011).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pierre Miossec.

Ethics declarations

Competing interests

The author declares no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Cite this article

Miossec, P. Translational medicine in RA—time for change. Nat Rev Rheumatol 10, 74–76 (2014). https://doi.org/10.1038/nrrheum.2013.204

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrrheum.2013.204

This article is cited by

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing